医学
阿法替尼
内科学
皮疹
肿瘤科
临床终点
不利影响
养生
临床研究阶段
临床试验
粘膜炎
索拉非尼
相伴的
头颈部鳞状细胞癌
头颈部
阶段(地层学)
队列
毒性
病态的
外科
中性粒细胞减少症
癌
低钾血症
新辅助治疗
完全响应
基底细胞
疾病
进行性疾病
存活率
白细胞减少症
封锁
放射治疗
腹泻
作者
Zhigong Wei,Huijiao Chen,Dejuan Wang,Zheng Jiang,Yiyan Pei,Le-Yu Li,Feng Wang,Jing Jin,Z. Liu,Fei Chen,Jun Li,Xingchen Peng
标识
DOI:10.1038/s41467-025-63978-y
摘要
Despite receiving standard treatments, patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) often still face significant risks of disease recurrence or metastasis. In this phase II neoCHANCE-1 study (NCT05517330), we evaluated the efficacy and safety of the dual-targeted blockade of the PD-1 and EGFR pathways in a neoadjuvant setting. The primary endpoint was the major pathological response (MPR) rate. The secondary endpoints included the pathological complete response (pCR) rate, overall response rate (ORR), safety, disease-free survival (DFS), and overall survival (OS). A cohort of 25 patients was subjected to a treatment regimen consisting of tislelizumab for two cycles, concomitant with daily intake of afatinib for six weeks. Among the 23 evaluable patients, eight (35%; 95% CI, 16%–57%) achieved an MPR that met the prespecified endpoint, and four (17%, 95% CI, 5%–39%) achieved a pCR of the primary tumor. The ORR was 48% (12/25, 95% CI: 28%–69%). The most common grade 3–4 adverse events included diarrhea (5/25), hypokalemia (4/25), and rash (3/25). This study highlights the encouraging antitumor activity, manageable toxicity profile, and promising immune activation caused by neoadjuvant tislelizumab plus afatinib treatment of HNSCC, which deserves further investigation. Immunotherapy has improved patient outcomes in those with metastatic or recurrent head and neck squamous cell carcinoma (HNSCC) but less so in the neoadjuvant setting. Here, the authors report the efficacy, safety and exploratory biomarker analysis of a phase II clinical trial investigating neoadjuvant tislelizumab (anti-PD-1) and afatinib (EGFR TKI) in patients with locally advanced HNSCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI